Multiple Genetic Variants in Telomere Pathway Genes and Breast Cancer Risk by Shen, Jing et al.
Multiple genetic variants in telomere pathway genes and breast
cancer risk
Jing Shen1,*, Marilie D. Gammon2, Hui-Chen Wu1, Mary Beth Terry3, Qiao Wang1, Patrick T.
Bradshaw2, Susan L. Teitelbaum4, Alfred I. Neugut3, and Regina M. Santella1
1Department of Environmental Health Sciences, Mailman School of Public Health, Columbia
University, New York, NY 10032, USA
2Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina,
Chapel Hill, NC 27599, USA
3Department of Epidemiology, Mailman School of Public Health, Columbia University, New York,
NY 10032, USA
4Department of Community and Preventive Medicine, Mt. Sinai School of Medicine, New York, NY
10029, USA
Abstract
Purpose—To explore the etiologic role of genetic variants in telomere pathway genes and breast
cancer risk.
Methods—A population-based case-control study — the Long Island Breast Cancer Study Project
(LIBCSP) was conducted, and 1,067 cases and 1,110 controls were included in the present study.
Fifty-two genetic variants of nine telomere related genes were genotyped.
Results—There were a total of seven single nucleotide polymorphisms (SNPs) showing significant
case-control differences at the level p<0.05. The top three statistically significant SNPs under a
dominant model were TERT-07 (rs2736109), TERT-54 (rs3816659) and POT1-03 (rs33964002). The
ORs were 1.56 (95%CI: 1.22-1.99) for TERT-07 G-allele, 1.27 (95%CI: 1.05-1.52) for TERT-54 T-
allele and 0.79 (95%CI: 0.67-0.95) for POT1-03 A-allele. TERT-67 (rs2853669) was statistically
significant under a recessive model; the OR of the CC genotype was 0.69 (95%CI: 0.69-0.93)
compared with the T-allele. However, none of the SNPs retained significance after Bonferroni
adjustment for multiple testing at the level of p<0.001 (0.05/52) except for TERT-07. When restricted
to Caucasians (94% of the study subjects), a stronger association for the TERT-07 G-allele was
observed with an OR of 1.60 (95%CI: 1.24-2.05, p=0.0002). No effect modifications were found for
variant alleles and menopausal status, telomere length, cigarette smoking, BMI status and family
history on breast cancer risk.
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Translational Relevance
We examined 52 genetic variants in telomere maintenance genes and relationships with breast cancer risk in a population-based case-
control study. Seven single nucleotide polymorphisms (SNPs) showed significant associations with breast cancer (p<0.05). The top three
significant ORs under a dominant model were 1.56 (95%CI: 1.22-1.99) for the TERT-07 G-allele, 1.27 (95%CI: 1.05-1.52) for the
TERT-54 T-allele and 0.79 (95%CI: 0.67-0.95) for the POT1-03 A-allele but only TERT-07 retained significance after 100,000 random
permutation analyses and Bonferroni adjustment for multiple testing at the level of p<0.001 (0.05/52). Our findings, if confirmed by
other studies, may have significant clinical utility in identifying high-risk individuals and improving early diagnosis of breast cancer.
Evaluation of the role of these SNPs in predicting breast cancer prognosis is a future plan.
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Conclusions—Four SNPs in TERT and POT1 genes were significantly related with overall breast
cancer risk. This initial analysis provides valuable clues for further exploration of the biological role
of telomere pathway genes in breast cancer.
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Introduction
Molecular epidemiological studies undertaken to uncover genetic risk factors for beast cancer
have expanded from examining single/several genetic variants to exploring the role of multiple
polymorphisms involved in different biological pathways for tumorigenesis. Recently, five
genome-wide association (GWA) studies focused on breast cancer risk have been completed.
Only seven novel single nucleotide polymorphisms (SNPs) (rs1219648, rs2981582,
rs3803662, rs889312, rs3817198, rs13281615 and rs13387042) among four genes (FGFR2,
TNRC9, MAP3K1 and LSP1) and two loci (2q35 and 16q12) were identified as potentially
related to breast cancer risk through screening 150,000 to 528,000 SNPs (1-5). Thus, we are
far from understanding the “polygenic” characteristic of breast cancer. At the same time, none
of the SNPs identified in the GWA studies are involved in the DNA damage/repair pathway,
one of the well recognized mechanisms underlying breast cancer risk (6;7). Although GWA
studies screen a mass of known SNPs covering the whole genome, this approach may not
always be the most optimal for detecting certain main effects of important variant alleles.
Systematic analysis of candidate breast cancer genes have found that more than one third
(37.7%) are involved in an unknown pathway, suggesting that there are still many genomic
gaps that need to be filled in (8-10). A pathway-based approach may be an ideal alternative to
contribute to our knowledge of critical biological pathways in breast cancer risk.
Telomere pathway genes are essential for maintaining genomic integrity and stability by
regulating telomere length and the higher-order structure of the protein complex at the end of
linear chromosomes (11-15). A dysfunctional telomere pathway may lead to less efficient DNA
damage repair, genomic instability, and ultimately, initiate tumorigenesis. Theoretically,
functional genetic variants in telomere pathway genes, which potentially influence telomere
length, activity of telomerase and the protein-complex, might play a key role in the process of
breast cancer development. Previous studies have observed that genetic variation in telomere-
binding proteins (including TERF1, TERF2, POT1 and TINF2, etc.) might accelerate telomere
shortening and dysfunction (16;17), and data on the TERF1 first exon deletion and null
mutations in murine embryonic stem cells indicated its negative regulator role for telomere
length and telomeric structures (18;19).
Two genome-wide studies measuring mutant telomere maintenance genes in yeast identified
272 related genes altering telomere length (lengthening or shortening telomeric DNA
sequence) (20;21). Several functional SNPs in human telomerase reverse transcriptase
(TERT) have been noted to positively affect enzyme activity, mRNA expression and telomere
length (22-24), although not confirmed by another study (25). However, the only population-
based study, conducted in Poland, did not identify any significant associations between 24
SNPs or haplotypes within five telomere-related genes (POT1, TEP1, TERF1, TERF2 and
TERT) and breast cancer risk. Only three correlated SNPs in TERT indicated an association
with reduced breast cancer risk among the subgroup of individuals with a family history of
breast cancer (26). Thus, the role of genetic variants in telomere pathway genes and breast
cancer risk is unclear, especially at the population level. In the current study, we utilized the
population-base case-control data and DNAs from Long Island Breast Cancer Study Project
(LIBCSP) to examine 52 polymorphisms of nine key genes (PINX1, POT1, RAD18, TERC,
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TERF1, TERF2, TERF2IP, TERT and TNKS) in the telomere pathway and analyzed their
relationships with breast cancer risk.
Materials and Methods
Study Population
The LIBCSP was conducted with approval from participating institutional review boards, and
in accordance with an assurance filed with and approved by the United States Department of
Health and Human Services. The study methods have been described in detail previously
(27). In brief, case eligibility included adult female residents of Nassau and Suffolk counties
on Long Island, NY, who were of any age or race, who spoke English, and were newly
diagnosed with in situ or invasive breast cancer between August 1, 1996, and July 31, 1997.
Potentially eligible controls were frequency matched to the expected age distribution of the
cases and identified through random digit dialing for women under age 65 years, and through
the Center for Medicare and Medicaid Services (CMS) rosters for women 65 and over. Eligible
controls were defined as women who spoke English, and resided in the same Long Island
counties as the cases, but with no personal history of breast cancer. In-person interviews were
completed for 82.1% of cases (n = 1,508) and 62.8% of controls (n = 1,556). Of those who
completed the main questionnaire, 73.1% of cases (1,102) and 73.3% of controls (1,141)
donated a blood sample. Of these, 1,067 cases and 1,110 controls with enough DNA for
genotyping were included in the present study. Ethnicity (94% white, 4% African American
and 2% other) and age (ranging from 20-98 years) distributions were similar between
respondents who completed the main questionnaire and the subjects analyzed in the present
study (data not shown).
Questionnaire Data Collect
In-person interviews were conducted within a few months of diagnosis by trained personnel.
The main questionnaire collected information on known and suspected risk factors for breast
cancer, including family history of breast cancer, reproductive history, menopausal status,
exogenous hormone use, body mass index (BMI), history of alcohol use and active cigarette
smoking. Menopausal status was based on the subject's self-reported information at the baseline
interview. Postmenopausal status was defined as having the last menstrual period at least 6
months prior to the reference date or having both ovaries removed (28). Ever cigarette smoker
was defined as smoking within the last 12 months prior to the reference date or who quit
smoking more than 12 months prior to the reference date (29). BMI was calculated from self-
reported weight and height data using the formula weight (kg)/height (m2). BMI just prior to
the reference date was categorized as <25 or ≥25 based on the World Health Organization
definition of overweight (30).
Telomere Pathway Genes and Genetic Variants Select
A total of 24 genes were identified within the human telomere pathway by a literature review
(13;31-33). Information on genetic variation among these genes was collected from publicly
available databases (dbSNP a; UCSC Genome Bioinformatics b; GeneCards c and
SNP500Cancer d). Totally, 6,515 SNPs are known for these genes. The nine genes (PINX1,
POT1, RAD18, TERC, TERF1, TERF2, TERF2IP, TERT and TNKS) considered as candidate
targets in the current study are those with previous evidence related to cancer development,
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Potential functional variants were chosen from these genes according to the criteria: (a) a minor
allele frequency ≥5% and heterozygosity ≥ 0.1 in Caucasians; and (b) >80% homology between
human and rat/mouse genomes; or (c) located in exons (including untranslated regions), exon-
intron junctions, or promoter regions; or (d) previous evidence indicating a significant
functional effect; or (e) previous findings indicating associations with cancer risk or telomere
function. Fifty-five genetic variants were selected at the beginning of the current study, and
three of the SNPs were excluded because they were not in Hardy Weinberg equilibrium and
minor allele frequency was <5%. Finally, 52 variants were evaluated in the final analyses.
Laboratory Methods
Genomic DNA was isolated by standard phenol and chloroform/isoamyl alcohol extraction
and RNase treatment as previously described (34) and genotyped on a BioTrove OpenArray™
system with TaqMan assays. For the BioTrove platform, DNAs (2ul, 200ng) were used to
detect 32 SNPs in a plate with 3,072 through-holes arranged in a pattern of 96 sub-arrays. The
PCR mixtures for 96 samples included 1× (144ul) TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, CA), 1% (14.4ul) Pluronic F38 (BioTrove, Woburn, MA),
0.5% (9.6ul) glycerol (Sigma–Aldrich, St. Louis, MO), 0.05 mg/ml (1.5ul) BSA (Sigma–
Aldrich) and 5.0ul PCR grade water (Sigma–Aldrich). The OpenArray™ AutoLoader enables
loading of the mixed solution (DNA and PCR mixture) onto an OpenArray™ plate from a 384-
well plate. The PCR thermal cycling protocol consisted of 92°C for 10 min followed by 50
cycles of 92°C for 15s, 55°C for 1 min and 72°C for 1 min (imaging step). Following
amplification, amplicon dissociation was measured by cooling the PCR array to 65°C then
slowly heating to 92°C for 1°C per min, with images collected every 0.25°C.
The “Image” program was used to obtain the three genotyping clusters in the scatter plot
(Supplemental Figure 1). Samples that failed to amplify were repeated, and samples that failed
on the second run were scored as missing. SNPs that could not be well genotyped on the
BioTrove OpenArray™ system were genotyped by TaqMan assays on 384 well plates
(Supplemental Figure 2 showing one example of a TaqMan assay scatter plot). Genotype
reproducibility was verified by randomly duplicated DNAs. The overall consistent rates were
ranged from 96.4-97.7%. All genotyping was performed with the laboratory personnel blinded
to the subject's case-control status.
Telomere length was measure by a quantitative PCR (Q-PCR) method described by Cawthon
(35), and data has been reported previously (36).
Statistical Analysis
Allele frequencies were calculated, and Hardy-Weinberg equilibrium determined for each SNP
(37). Age at reference-adjusted logistic regression assessed associations of individual SNPs
with breast cancer risk, and odds ratios (OR) and corresponding 95% confidence intervals (CI)
were estimated (38). All SNPs were first evaluated by a co-dominant (additive) model. If the
estimated ORs for heterozygous and homozygous genotypes were in the same direction, a
dominant model was also used. A recessive model was used only when the ORs for
heterozygous and homozygous genotypes were in the opposite direction. Linkage
disequilibrium (LD) structure and haplotype blocks (frequencies) were estimated for genes
with data on at least 5 SNPs by the Expectation Maximization Algorithm (EM-algorithm)
applied in Haploview (39). Bonferroni adjustment for multiple testing at the level of p<0.001
(0.05/52) was considered as significance. At the same time, a two-tailed significant level of
0.05 (permutation p-value) was used after 100,000 permutations corrected for multiple testing
bias (39). Genetic variants showing case-control difference at the level of p<0.05 were further
analyzed after stratification by menopausal, smoking status, BMI and telomere length. One
way ANOVA was used to compare the means of telomere length across the various genotypes
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for each gene. The potential functions of significant SNPs were estimated by PupaSuite
(Spanish National Genotyping Center, Valencia, Spain)e.
A variable was considered a confounder if the estimated OR for a main effect changed 10%
or more when the covariate was included in the logistical regression model. A number of
covariates (family history of breast cancer in a first-degree relative, history of benign breast
disease, age at menarche, parity, lactation, months of lactation, age at first birth, number of
miscarriages, history of fertility problems, use of contraceptives or hormone replacement
therapy, alcohol drinking, race, education, religion and marital status) were evaluated, and no
confounders were found. Therefore, only age-adjusted results are presented. All statistical
analyses were completed using Statistical Analysis System 9.0 (SAS Institute, Cary, NC).
Results
In single polymorphism analyses, there were a total of seven SNPs showing significant case-
control differences at the level p<0.05 from the 52 tested (Table 1). The top three statistically
significant SNPs under a dominant model were TERT-07 (rs2736109) with p=0.0004, and
TERT-54 (rs3816659) and POT1-03 (rs33964002) with ps=0.01. The ORs were 1.56 (95%CI:
1.22-1.99) for the TERT-07 G-allele, 1.27 (95%CI: 1.05-1.52) for the TERT-54 T-allele and
0.79 (95%CI: 0.67-0.95) for the POT1-03 A-allele. One SNP (TERT-67 rs2853669) was
statistically significant at a p value of 0.01 under a recessive model. The OR of the CC genotype
was 0.69 (95%CI: 0.69-0.93) compared with one or two copies of the T-allele. However, only
one SNP (TERT-07 rs2736109) still retained significance after Bonferroni adjustment for
multiple testing at the level of p<0.001 (0.05/52). This finding was strengthened when we
restricted the analysis to the subset of women who are Caucasian, who account for 94% of the
current study subjects. The OR was 1.60 (95%CI: 1.24-2.05, p=0.0002) for the TERT-07 G-
allele. Permutation analysis of 105 random replications showed similar results for the two
TERT SNPs (TERT-07 rs2736109 and TERT-54 rs3816659), which achieved a statistically
significant level of 0.05 (Figure 1).
Two haplotype blocks were constructed for TERT (Figure 2). Although no statistically
significant haplotype was found in block 1, SNP TERT-07 (rs2736109) displayed a strong
linkage disequilibrium (D′=0.91) with a functional SNP TERT-67 (rs2853669). Within block
2, a common haplotype containing the TERT-21 G–allele and TERT-54 T-allele showed a
significant association with increased breast cancer risk (p=0.001), and 105 repeated
permutation analysis confirmed this association with borderline significance (p=0.056). No
other inferred haplotypes were associated with breast cancer risk (Figure 2).
Subgroups analyses showed that the ORs of the TERT-07 G-allele, TERT-54 T-allele and
TERT-67 CC genotype for pre-menopausal women were, respectively, 1.48 (95%CI:
0.96-2.28), 1.47 (95%CI: 1.06-2.04) and 0.67 (95%CI: 0.42-1.09), which were not statistically
significantly different from those for post-menopausal women (1.69 (95%CI: 1.24-2.29), 1.12
(95%CI: 0.89-1.41) and 0.69 (95%CI: 0.47-1.00), respectively). This result indicates that there
is no heterogeneity for breast cancer risk by menopausal status (Table 2). The increased breast
cancer risk observed for the TERT-07 G-allele among the shortened telomere length subgroup
was statistically significant (OR=1.81, 95%CI: 1.25-2.61), but did not reach significance for
the subgroup with telomere length above the median (OR=1.36, 95%CI: 0.97-1.92). Therefore,
there was no heterogeneity in breast cancer risk by telomere length status (Table 3). Similarly,
no effect modifications between those variant alleles and breast cancer risk were observed for
subgroups stratified by cigarette smoking, BMI status and family history (data not shown).
ehttp://pupasuite.bioinfo.cipf.es/
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To the best of our knowledge, this is the largest association study exploring genetic variants
in the telomere pathway (52 SNPs among nine genes) and breast cancer risk. Our results provide
evidence to support the association of genetic polymorphisms in telomere pathway genes and
breast cancer risk. Four SNPs (p≤0.01) in TERT (rs2736109, rs2853669, rs3816659) and
POT1 (rs33964002) were significantly related to overall breast cancer risk under dominant or
recessive models. One of the SNPs (TERT-07 rs2736109) still retained significance after a
105 repeated permutation tests (p<0.05) and the conservative Bonferroni adjustment for
multiple testing at the level of p<0.001. With a moderate sample size (1,067 cases and 1,110
controls) for a genetic association study and the high frequencies (30.5-62.3%) of the four
significant variant alleles in the current study, we have reasonable power to determine the main
effects of TERT and POT1 variants on breast cancer predisposition.
Human telomerase reverse transcriptase (TERT) is an important catalytic subunit of telomerase
and determines telomerase activity (40-42). TERT, located at chromosome 5p15.33, includes
16 exons with at least 508 known SNPs. Two functional SNPs (TERT-08 rs2735940 and
TERT-67 rs2853669) have been found within the promoter region (T/C transitions at 1381bp
and 244bp upstream of the transcription-starting site ATG) (22;23). The TERT-08 CC genotype
had lower telomerase activity and was associated with shorter telomere length among healthy
Japanese and coronary artery disease patients compared with T-allele carriers (22;43).
However, this association was not observed in a Swedish population study (25). A previous
study among Polish women observed that carrying the TERT-08 TT genotype has no overall
relationship with breast cancer risk (OR=0.98, 95%CI: 0.83-1.15), but a decreased risk was
observed for individuals with a family history of breast cancer (OR=0.73, 95%CI: 0.53-1.00)
(26). Our data did not show any significant genotype-breast cancer association for this SNP,
and also no genotype-family history interaction was observed. In a recent study of 66 non-
small cell lung cancer tissues, telomerase activity was significantly decreased in carriers of the
TERT-67 CC genotype compared to those with the TT genotype (p=0.03), while telomere
length was longer in those with the CC compared to TT genotype, but it did not reach statistical
significance (p=0.06) (23). Our results for this SNP indicated that the CC genotype was
correlated with a significant decreased breast cancer risk (OR=0.69, 95%CI: 0.69-0.93), but
this association was not modified by breast cancer family history as found by a previous study
(26). It is consistent with a recent observation that TERT-67 CC genotype was significantly
associated with decreased breast cancer risk (OR=0.65, 95%CI: 0.46-0.92) in a Swedish
population (44). This result is supported by bioinformatics functional analysis (PupaSuite),
which indicates that the TERT-67 variant allele disrupts transcription factor binding sites,
presumably altering the activity of telomerase.
Until now, no experimental functional data have been reported for TERT-07 (rs2736109) and
TERT-54 (rs3816659) that had significant positive associations with increased breast cancer
risk under a dominant model in the current study. Bioinformatics PupaSuite exploration also
did not indicate any potential functions. TERT-07, with the most significant p-value in mono-
variable analysis, is sited within the gene's promoter region and located in the same haplotype
block as TERT-67, a known functional SNP. A strong linkage disequilibrium (D′=0.91) was
observed between TERT-07 and TERT-67 (Figure 2), indicating a potentially functional
complementation on modification of telomerase function and breast cancer risk. A recent GWA
study including 29,603 cancer cases and 45,846 controls found TERT-01 SNP (rs2736098)
was significantly associated with increased risks for basal cell carcinoma, bladder, lung and
prostate cancers (ORs ranged from 1.13-1.21, p<1.3×10-4) (45). Other GWA studies observed
that a TERT-69 SNP (rs2736100) was significantly related with increased risks for lung cancer
(OR=1.18, 95%CI: 1.10-1.26, p=4×10-6) (46), glioma (OR=1.27, 95%CI: 1.19–1.37,
p=1.5×10-17) (47) and lung fibrosis (OR=2.11, 95%CI: 1.61-2.78, p=2.9×10-8) (48). Because
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the most significant SNP (TERT-07) found in the current study has no available genotyping
data in the HapMap project, it is difficult to obtain the direct linkage disequilibrium parameters
for this SNP and the SNPs (TERT-01 and TERT-69) showing significance in GWA studies.
We downloaded a Caucasian dataset (22 subjects) from the website of Genome Variation
Serverf that contains the three SNPs to estimate the LD parameters. A strong linkage
disequilibrium was found between TERT-07 and TERT-01 (D′=0.87, r2=0.57), but not for
TERT-69. Whether these SNPs located within this narrow genomic region (about 11kb) have
a similar etiologic role in breast tumorigenesis needs further evaluation.
That no significant interplay for the TERT-07 variant allele and telomere length on breast cancer
risk was noted in the current study suggests that this variant allele is less likely to influence
breast cancer risk by directly impacting telomere length. It is biologically plausible that when
rapid shortening of telomere length is truly caused by this variant allele, the response of
proliferating cells leads to immediate initiation of a feedback mechanism to increase telomerase
activity, and sustain telomere function by extending telomere length (49;50). Therefore, an
association between the TERT variant allele and shortened telomere length may be shielded,
and unable to be detected easily. This is consistent with our observation of a detectable
genotype-outcome (breast cancer) association, but without a genotype-phenotype (telomere
length) connection. However, the exact underlying mechanisms require further laboratory
functional validation or determination of combined biomarkers in the telomere pathway (global
or chromosome-specific telomere lengths, activities of telomerase components and telomere-
proteins expression) to clarify.
Another functional genetic variation in TERT has been found (MNS16A), which is a 23bp (or
26bp) tandem repeat sequence TCC TCT TAT (cat) CTC CCA GTC TCA TC in the putative
promoter region of the anti-sense RNA transcript (24). The short (S) allele of MNS16A has
been associated with increased expression of hTERT mRNA in telomerase positive cell lines
and primary lung cancer tissues (24). A recent study observed that carrying the variant S allele
was associated with significantly increased breast cancer risk (OR= 1.50, 95%CI: 1.15–1.96)
among Chinese women (51). We found no significant relationship between the S allele and
breast cancer predisposition (OR=1.05, 95%CI: 0.89-1.25), and a more diversified distribution
of MNS16A genotypes (9 alleles) in the current study. This is consistent with a report on a
Caucasian case-control study of malignant gliomas (10 alleles) (52), but different from a breast
cancer study in Chinese women (only 4 alleles) (51). These data indicate that the ethnic
background might have a significant influence on the association of telomere genetic variation
and breast cancer.
Little is known about the impact of POT1 genetic variation on telomere function and cancer
risk. Although POT1 might function as a negative regulator of telomere length by directly
inhibiting telomerase activity or controlling telomeric DNA substrate access to telomerase in
human cells (53;54), two previous population studies did not observe any association between
POT1 polymorphisms and breast or lung cancer (26;55). Our study, for the first time, provides
some evidence that several POT1 polymorphisms (rs7794637, rs33964002, rs7784168 and
rs10250202) might have main effects on breast cancer risk. However, data on these SNPs did
not reach statistical significance for the 105 permutation analysis or a more conservative
Bonferroni multiple testing. Functional evaluation using PupaSuite also did not note any
functionality. Therefore, these findings should be interpreted with caution until laboratory
functional validation or independent replication in a population study is obtained.
The strengths of current study include the population-based study design with a relatively large
sample size; a moderate number of SNPs within the same pathway examined and an
fhttp://gvs.gs.washington.edu/GVS/
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intermediate phenotype marker (telomere length) used. The extensive information on known
breast cancer risk factors and other co-variables obtained from questionnaires allowed us to
control for potential confounders and evaluate effect modifications in the data analysis. By
analyzing SNPs in telomere pathway genes, we identified one promising candidate gene
(TERT) whose role should be confirmed in further independent replication studies. At the same
time, a fine mapping study with high-density SNPs within the target region also would be
helpful in identifying the causal variants for sporadic breast cancer. In addition to genetic
variants, epigenetic alterations, especially telomere specific gene hypermethylation and
hypomethylation in subtelomeric regions, are also involved in the regulation of telomerase
activity and telomere length maintenance. Our inability to evaluate these potential genetic-
epigenetic modifications during breast cancer development is one of the limitations of the
current study. Furthermore, we had no data on telomerase activity that might impact breast
cancer risk by modifying telomere length or genetic variants. Due to the multiple comparisons
in our data analysis, and the lack of an independent study to provide additional supportive
evidence, we also could not completely rule out the possibility of false positive findings.
However, using the Bonferroni adjustment and permutation analyses whenever feasible, we
should have minimized this possibility.
In conclusion, our study identified a few promising SNPs in telomere pathway genes that are
potentially associated with breast cancer risk, although the OR for each SNP was modest in
magnitude. These findings provide additional data to support the hypothesis that breast cancer
is a polygenic trait with multiple pathway abnormalities. If replicated by additional population
studies, it will delineate a comprehensive picture on the etiological role of telomere pathway
genes in breast cancer predisposition, and has significant clinical applications in identifying
high-risk individuals and improving early diagnosis.
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Results from 105 permutation tests for 4 promising SNPs of TERT. Two SNPs (TERT-07
rs2736109 and TERT-54 rs3816659) showed statistically significant associations with breast
cancer risk (permutation p<0.05).
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A. TERT gene haplotype blocks. Two haplotype blocks were constructed for TERT. Within
block 1, SNP TERT-07 (rs2736109), with the most significant p-value in mono-variable
analysis, showed a strong linkage disequilibrium (D′=0.91) with a functional SNP TERT-67
(rs2853669). Two SNPs of TERT-01 (rs2736098) and TERT-69 (rs2736100) significantly
related with several cancer risks in recent GWA studies, were located near the haplotype block
1 (1,263 to 8,833bp away). B. TERT common haplotypes and breast cancer risk after 105
permutation tests. Haplotype GT within block 2 showed a borderline significant permutation
p value.
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